Sichuan Goldstone Asia Pharmaceutical300434.SZValuation Analysis

As of Oct 19, 2026, Sichuan Goldstone Asia Pharmaceutical (300434.SZ) trades at a P/E of 31.00x, P/B of 1.92x, P/S of 5.10x, and a dividend yield of 0.66%.
Longitudinal percentile comparison: P/E sits at the 41st percentile over the trailing 10Y window (vs. 37th percentile over 3Y); P/B sits at the 71st percentile over the trailing 10Y window (vs. 92nd percentile over 3Y); P/S sits at the 75th percentile over the trailing 10Y window (vs. 96th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 42nd percentile within its industry and the 43rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.66%, ranking at the 61st percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 30.3 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Sichuan Goldstone Asia Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.